NK cells derived from CD34+ hematopoietic cells (Glycostem)

N/A

Report date: 2026/03/17 20:00:15

Base Information

Drug NameNK cells derived from CD34+ hematopoietic cells (Glycostem)
Drug Alias NameInaleucel来自CD34+造血细胞的NK细胞Allogeneic UCB-NK cells (Glycostem)GCT NK cells (Glycostem)oNKord
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood progenitor cells-derived
Mechanisms of ActionImmunostimulantsNatural killer cell replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlandsGermany +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlycostem
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRadboud University Medical CenterGlycostem
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A